1734 — Sinphar Pharmaceutical Co Balance Sheet
0.000.00%
- TWD5.81bn
- TWD6.71bn
- TWD3.15bn
- 72
- 51
- 83
- 82
Annual balance sheet for Sinphar Pharmaceutical Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1,194 | 1,245 | 1,244 | 1,081 | 1,178 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 469 | 593 | 685 | 643 | 642 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 2,540 | 2,703 | 2,778 | 2,649 | 2,624 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3,321 | 3,247 | 3,204 | 3,278 | 3,316 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 6,127 | 6,221 | 6,185 | 6,251 | 6,298 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1,330 | 1,534 | 1,446 | 1,205 | 1,423 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 3,382 | 3,499 | 3,255 | 3,153 | 3,035 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 2,744 | 2,722 | 2,930 | 3,098 | 3,263 |
| Total Liabilities & Shareholders' Equity | 6,127 | 6,221 | 6,185 | 6,251 | 6,298 |
| Total Common Shares Outstanding |